title: Extensive exfoliative dermatitis induced by non-ionic contrast medium Iodixanol (Visipaque) used during percutaneous coronary intervention.
abstract: We report a case of extensive exfoliative dermatitis in a patient appearing 3 days after intracoronary administration of non-ionic contrast medium Iodixanol (Visipaque) during the primary percutaneous coronary intervention. The patient presented with acute myocardial infarction and has never exposed to any X-ray contrast medium. The patient was successfully treated with corticosteroid, antihistamines and antibiotics for the prevention of secondary bacterial infection. The patient was recovered 8 days after the anti-allergic medical management. This case can be a rare example of late-onset allergic reaction to a non-ionic contrast medium Iodixanol presented with extensive exfoliative dermatitis.
authors.forename: Cheol Ung
authors.initials: CU
authors.lastname: Choi
authors.forename: Seung-Woon
authors.initials: SW
authors.lastname: Rha
authors.forename: Soon Yong
authors.initials: SY
authors.lastname: Suh
authors.forename: Jin Won
authors.initials: JW
authors.lastname: Kim
authors.forename: Eung Ju
authors.initials: EJ
authors.lastname: Kim
authors.forename: Chang Gyu
authors.initials: CG
authors.lastname: Park
authors.forename: Hong Seog
authors.initials: HS
authors.lastname: Seo
authors.forename: Dong Joo
authors.initials: DJ
authors.lastname: Oh
mesh_terms: D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000379:methods*; D002637:Chest Pain / Q000175:diagnosis / Q000209:etiology; D003287:Contrast Media / Q000009:adverse effects*; D017023:Coronary Angiography; D003873:Dermatitis, Exfoliative / Q000139:chemically induced* / Q000188:drug therapy / Q000503:physiopathology; D054855:Drug-Eluting Stents; D004636:Emergency Service, Hospital; D005500:Follow-Up Studies; D006634:Histamine H1 Antagonists / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000000981:diagnostic imaging / Q000628:therapy*; D018570:Risk Assessment; D012720:Severity of Illness Index; D013256:Steroids / Q000627:therapeutic use; D014283:Triiodobenzoic Acids / Q000009:adverse effects*
chemical_list: D003287:Contrast Media; D006634:Histamine H1 Antagonists; D013256:Steroids; D014283:Triiodobenzoic Acids; C044834:iodixanol